You just read:

FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis

News provided by

Eli Lilly and Company

Apr 23, 2018, 08:11 ET